Food supplements like curcumin and boswellia serrata have been used traditionally for anti-inflammatory purposes. A well-known problem of these substances in their natural form is the low bioavailability. Micellization of these substances has been shown to increase the bioavailability significantly and thereby the clinical efficacy. The clinical value of these micellized substances has been presented in numerous clinical studies and in particular in patients with acute COVID-19. This study aims to examine the effect of a mixture of micellized curcumin, boswellia serrata and ascorbic acid on patients with long COVID.

The participants will be asked to take the micellized supplements daily, at home for 6 weeks. During this 6 weeks several questionnaires will be taken to asses general health-related quality of life. Follow-up measurements will be done at 14 weeks.

Inclusion Criteria:

• Patients with confirmed SARS-CoV-2 infection at least 28 days prior to study participation
• Patients who are experiencing symptoms of PACS (with a PCFS of 1 or higher)
• 18 years or older and younger than 85
• Good understanding of written German

Exclusion Criteria:

• Currently under pharmacological treatment for PACS
• Any planned medical surgery or intervention where medication intake is necessary in the coming 14 weeks
• Allergy to curcumin or Boswellia
• Active malignancy
• Medical history of Human Immunodeficiency Virus (HIV) infection, or any serious immunocompromised state.
• Pregnancy (or planned pregnancy in the coming 14 weeks) ( - Patients who are taking anticoagulants or have diabetes type I or II are only allowed to participate if their general practitioner is informed)

Data are available for researchers upon request.

The data will become available as soon as the results are published. The availability of the data is 5 years.

i) Affiliated researcher, 2) researcher must be able to demonstrate that accessing the raw study data is necessary to be able to conduct his/her research project